Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-03-2013 | Original Paper

Long noncoding RNA CCAT1, which could be activated by c-Myc, promotes the progression of gastric carcinoma

Authors: Feng Yang, Xuchao Xue, Jianwei Bi, Luming Zheng, Kangkang Zhi, Yan Gu, Guoen Fang

Published in: Journal of Cancer Research and Clinical Oncology | Issue 3/2013

Abstract

Purpose

Long noncoding RNAs (lncRNAs) have been shown to have functional roles in cancer biology and are deregulated in many tumors. The specific aim of this study was to determine the role of a long noncoding RNA CCAT1 in the progression of gastric carcinoma and discover which factors contribute to the deregulation of CCAT1.

Methods

A computational screen of CCAT1 promoter was conducted to search for transcription-factor-binding sites. The association of c-Myc with the CCAT1 promoter in vivo was tested by chromatin immunoprecipitation assay. CCAT1 promoter activities were examined by luciferase reporter assay. The function of the c-Myc binding site in the CCAT1 promoter region was tested by a promoter assay with nucleotide substitutions in the putative E-box. The effect of CCAT1 on gastric carcinoma cell proliferation and migration was tested using in vitro cell proliferation and migration assays.

Results

CCAT1 levels were markedly increased in gastric carcinoma tissues compared with normal tissues. c-Myc directly binds to the E-box element in the promoter region of CCAT1, and when ectopically expressed increased promoter activity and expression of CCAT1. Nucleotide substitutions in the E-box element in the promoter region abrogated c-Myc-dependent promoter activation. The expression of CCAT1 and c-Myc shows strong association in gastric carcinomas. Moreover, abnormally expressed CCAT1 promotes cell proliferation and migration.

Conclusions

These data suggest that c-Myc induction of CCAT1 holds an important role in gastric carcinoma and implicate the potential application of CCAT1 in the treatment of gastric carcinoma.

Available only for authorised users

Barsyte-Lovejoy D, Lau SK, Boutros PC, Khosravi F, Jurisica I, Andrulis IL, Tsao MS, Penn LZ (2006) The c-Myc oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis. Cancer Res 66(10):5330–5337PubMedCrossRef

Calcagno DQ, Leal MF, Assumpcao PP, Smith MA, Burbano RR (2008) MYC and gastric adenocarcinoma carcinogenesis. World J Gastroenterol 14(39):5962–5968PubMedCrossRef

Calcagno DQ, Leal MF, Demachki S, Araujo MT, Freitas FW, Oliveira e Souza D, Assumpcao PP, Ishak G, de Arruda Cardoso Smith M, Burbano RR (2010) MYC in gastric carcinoma and intestinal metaplasia of young adults. Cancer Genet Cytogenet 202(1):63–66PubMedCrossRef

Cole MD, Henriksson M (2006) 25 years of the c-Myc oncogene. Semin Cancer Biol 16(4):241PubMedCrossRef

Dang CV, O’Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F (2006) The c-Myc target gene network. Semin Cancer Biol 16(4):253–264PubMedCrossRef

Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, Wang Y, Brzoska P, Kong B, Li R, West RB, van de Vijver MJ, Sukumar S, Chang HY (2010) Long noncoding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464(7291):1071–1076PubMedCrossRef

Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ (2009) Gastric cancer. Lancet 374(9688):477–490PubMedCrossRef

Huarte M, Guttman M, Feldser D, Garber M, Koziol MJ, Kenzelmann-Broz D, Khalil AM, Zuk O, Amit I, Rabani M, Attardi LD, Regev A, Lander ES, Jacks T, Rinn JL (2010) A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell 142(3):409–419PubMedCrossRef

Hung T, Wang Y, Lin MF, Koegel AK, Kotake Y, Grant GD, Horlings HM, Shah N, Umbricht C, Wang P, Kong B, Langerod A, Borresen-Dale AL, Kim SK, van de Vijver M, Sukumar S, Whitfield ML, Kellis M, Xiong Y, Wong DJ, Chang HY (2011) Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. Nat Genet 43(7):621–629PubMedCrossRef

Krzyzanowski PM, Muro EM, Andrade-Navarro MA (2012) Computational approaches to discovering noncoding RNA. Wiley Interdiscip Rev RNA 3(4):567–579PubMedCrossRef

Li L, Feng T, Lian Y, Zhang G, Garen A, Song X (2009) Role of human noncoding RNAs in the control of tumorigenesis. Proc Natl Acad Sci USA 106(31):12956–12961PubMedCrossRef

Milne AN, Carneiro F, O’Morain C, Offerhaus GJ (2009) Nature meets nurture: molecular genetics of gastric cancer. Hum Genet 126(5):615–628PubMedCrossRef

Moore MA, Attasara P, Khuhaprema T, Le TN, Nguyen TH, Raingsey PP, Sriamporn S, Sriplung H, Srivanatanakul P, Bui DT, Wiangnon S, Sobue T (2010) Cancer epidemiology in mainland South-East Asia—past, present and future. Asian Pac J Cancer Prev 11(Suppl 2):67–80PubMed

Moran VA, Perera RJ, Khalil AM (2012) Emerging functional and mechanistic paradigms of mammalian long non-coding RNAs. Nucleic Acids Res 40(14):6391–6400PubMedCrossRef

Muers M (2011) RNA: genome-wide views of long non-coding RNAs. Nat Rev Genet 12(11):742PubMedCrossRef

Nissan A, Stojadinovic A, Mitrani-Rosenbaum S, Halle D, Grinbaum R, Roistacher M, Bochem A, Dayanc BE, Ritter G, Gomceli I, Bostanci EB, Akoglu M, Chen YT, Old LJ, Gure AO (2012) Colon cancer associated transcript-1: a novel RNA expressed in malignant and pre-malignant human tissues. Int J Cancer 130(7):1598–1606PubMedCrossRef

Nobili S, Bruno L, Landini I, Napoli C, Bechi P, Tonelli F, Rubio CA, Mini E, Nesi G (2011) Genomic and genetic alterations influence the progression of gastric cancer. World J Gastroenterol 17(3):290–299PubMedCrossRef

Oster SK, Ho CS, Soucie EL, Penn LZ (2002) The myc oncogene: marvelouslY complex. Adv Cancer Res 84:81–154PubMedCrossRef

Panzitt K, Tschernatsch MM, Guelly C, Moustafa T, Stradner M, Strohmaier HM, Buck CR, Denk H, Schroeder R, Trauner M, Zatloukal K (2007) Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology 132(1):330–342PubMedCrossRef

Ponting CP, Oliver PL, Reik W (2009) Evolution and functions of long noncoding RNAs. Cell 136(4):629–641PubMedCrossRef

Solomon DL, Amati B, Land H (1993) Distinct DNA binding preferences for the c-Myc/Max and Max/Max dimers. Nucleic Acids Res 21(23):5372–5376PubMedCrossRef

Song L, Dai T, Xie Y, Wang C, Lin C, Wu Z, Ying Z, Wu J, Li M, Li J (2012) Up-regulation of miR-1245 by c-myc targets BRCA2 and impairs DNA repair. J Mol Cell Biol 4(2):108–117PubMedCrossRef

Spizzo R, Almeida MI, Colombatti A, Calin GA (2012) Long non-coding RNAs and cancer: a new frontier of translational research? Oncogene

Tsai MC, Spitale RC, Chang HY (2011) Long intergenic noncoding RNAs: new links in cancer progression. Cancer Res 71(1):3–7PubMedCrossRef

Wang KC, Chang HY (2011) Molecular mechanisms of long noncoding RNAs. Mol Cell 43(6):904–914PubMedCrossRef

Yan B, Wang Z (2012) Long Noncoding RNA: Its Physiological and Pathological Roles. DNA Cell Biol. doi:10.1089/dna.2011.1544

Zhang L, Hou Y, Ashktorab H, Gao L, Xu Y, Wu K, Zhai J (2010) The impact of C-MYC gene expression on gastric cancer cell. Mol Cell Biochem 344(1–2):125–135PubMedCrossRef

Zhu Y, Xiao X, Dong L, Liu Z (2012) Investigation and identification of let-7a related functional proteins in gastric carcinoma by proteomics. Anal Cell Pathol (Amst) 35(4):285–295

Title: Long noncoding RNA CCAT1, which could be activated by c-Myc, promotes the progression of gastric carcinoma
Authors: Feng Yang
Xuchao Xue
Jianwei Bi
Luming Zheng
Kangkang Zhi
Yan Gu
Guoen Fang
Publication date: 01-03-2013
Publisher: Springer-Verlag
Published in: Journal of Cancer Research and Clinical Oncology / Issue 3/2013
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-012-1324-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2013

Role of pharmacogenetics on adjuvant chemotherapy-induced neutropenia in Chinese breast cancer patients

Potential interactions of complementary and alternative medicine with cancer therapy in outpatients with gynecological cancer in a comprehensive cancer center

Direct progression of capsular invasive carcinomas from subcapsular focal hyperplasias induced by hypothyroidism-mediated tumor promotion in a rat two-stage thyroid carcinogenesis model

Brain metastases as the first symptom of lung cancer: a clinical study from an Asian medical center

Association of a common genetic variant of the IGF-1 gene with event-free survival in patients with HER2-positive breast cancer

Identification of proteins differentially expressed in adriamycin-resistant (pumc-91/ADM) and parental (pumc-91) human bladder cancer cell lines by proteome analysis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials